Overseas chief
Swedish clinical-stage biopharmaceutical company Aprea AB has named Christian Schade President and Chief Executive Officer. Before joining Aprea, Schade was CEO of US antiviral developer Novira Therapeutics, which was acquired by Johnson & Johnson last December.
Before that, he was Executive VP and CFO at dyslipidemia expert Omthera, where he led the sale of the company to AstraZeneca in 2013. Schade holds an MBA from the University of Pennsylvania and an AB from Princeton University. He currently serves on the Board of Directors of Integra Life Sciences Inc. and the Board of Directors of Indivior PLC and will be based in Boston.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium